FDA Approves Preservative-Free Latanoprost Drug for Elevated Intraocular Pressure
The FDA has approved Laboratoires Théa subsidiary Thea Pharma’s Iyuzeh (latanoprost ophthalmic solution) 0.005 percent to reduce elevated intraocular pressure in individuals with open-angle glaucoma or ocular hypertension.
Iyuzeh is a preservative-free formulation of latanoprost that “does not need to be manufactured, distributed, or stored at refrigerated temperatures,” the company said.
The drug, which is sold as Monoprost outside of the U.S., has shown consistent reductions in intraocular pressure in clinical trials in the U.S. and Europe.
Thea Pharma, Inc.
Thea Pharma, Inc. is an independent pharmaceutical company specializing in the commercialization of eye care products.
Established in 2019, Thea Pharma is the United States subsidiary of Laboratoires Théa, a global leader and pioneer in ophthalmics. We are committed to serve doctors that treat the anterior segment and ocular surface conditions.
Our goal is to deliver uncompromising care that allows all stakeholders to envision the future of ophthalmic treatment with eyes wide open.
December 22, 2022
